OmniAb (OABI) Stock

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from tradition.

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.

OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit.

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OmniAb is a long-term growth story. The company's Q2 earnings call reported nice growth in its projects and partners. As a newly formed company with lumpy revenues and limited liquidity, OmniAb still has work to do to support a bull thesis.

OmniAb, Inc. (NASDAQ:OABI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Kurt Gustafson - CFO Matthew Foehr - President, CEO Conference Call Participants Puneet Souda - Leerink Partners Robyn Karnauskas - Truist Securities Stephen Willey - Stifel Jack Siedow - Craig-Hallum Chad Wiatrowski - TD Cowen Brandon Carney - B.Riley Operator Good afternoon, and welcome to OmniAb, Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.